Cost-effectiveness of amivantamab plus lazertinib and osimertinib plus chemotherapy versus osimertinib monotherapy for first-line EGFR-mutated advanced Non-small cell lung cancer: an updated analysis.
INTRODUCTION: Osimertinib, amivantamab plus lazertinib, and osimertinib plus chemotherapy are the recommended first-line treatment options for EGFR exon 19 deletion or exon 21 L858R-mutated non-small cell lung cancer (NSCLC). One-way and probabilistic sensitivity analyses assessed model robustness, using a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY) or life year (LY) gained.
INTRODUCTION: Osimertinib, amivantamab plus lazertinib, and osimertinib plus chemotherapy are the recommended first-line treatment options for EGFR exon 19 deletion or exon 21 L858R-mutated non-small cell lung cancer (NSCLC). One-way and probabilistic sensitivity analyses assessed model robustness, using a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY) or life year (LY) gained.
What the study was
- Study design
- Journal Article
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Expert review of pharmacoeconomics & outcomes research
Why it surfaced
Score 6/10: Journal Article, human study, Exploratory. 🟢 NEAR_TERM_IMPLEMENTABLE — Near-term implementable finding
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.